The U.S. is set to see a wave of new weight-loss treatments hitting the market in the coming years, with drugmakers gearing up to launch an estimated 13 new products by 2027. This surge in obesity drug launches is in response to the growing demand for solutions to combat the rising rate of obesity in the country.
According to a report by Global Data, sales of weight-loss drugs have skyrocketed, with Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound leading the way and generating a combined $9.7B in global sales in 2023. Novo Nordisk is set to launch six new weight-loss products in the next five years, with CagriSema expected to generate $7.4B in sales by 2029. Eli Lilly also has two anti-obesity drugs in Phase 3 testing, including mazdutide which they plan to commercialize in collaboration with Innovent Biologics.
Other drug candidates in mid-stage development for obesity include Viking Therapeutics’ VK2735, Structure Therapeutics’ GSBR-1290, and Altimmune’s pemvidutide, among others. Despite the increasing number of weight-loss treatments in the pipeline, Global Data believes there will be enough demand to support multiple players in the market.
The success of recent blockbuster obesity drug launches has shown the viability of the market, prompting companies developing later entrants to expect great returns for their efforts. With projections that around 50% of US adults will be considered obese by 2030, the demand for effective weight-loss treatments is only expected to continue growing. Stay tuned for the latest developments in the world of weight-loss treatments on Jala News.
“Zombie enthusiast. Subtly charming travel practitioner. Webaholic. Internet expert.”